Immediate Impact
3 by Nobel laureates 2 from Science/Nature 54 standout
Citing Papers
New clinical trial design in precision medicine: discovery, development and direction
2024 Standout
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
2024 Standout
Works of Lance Wollenberg being referenced
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K -mutant Solid Tumors
2020
A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma.
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Lance Wollenberg | 133 | 75 | 16 | 51 | 23 | 307 | |
| May Y. K. Ho | 123 | 105 | 10 | 41 | 16 | 330 | |
| Nasser S. Al‐Shakliah | 151 | 105 | 4 | 33 | 29 | 368 | |
| Alexander Berg | 82 | 40 | 4 | 17 | 20 | 322 | |
| Asmaa A. Mandour | 92 | 26 | 21 | 13 | 27 | 286 | |
| Wenting Ni | 136 | 41 | 7 | 23 | 14 | 275 | |
| Е.O. Yablokov | 148 | 37 | 4 | 105 | 44 | 325 | |
| Jiye Chen | 128 | 75 | 12 | 14 | 24 | 324 | |
| Ning Ou | 96 | 38 | 3 | 30 | 28 | 329 | |
| Yuan Li | 114 | 56 | 13 | 29 | 27 | 330 | |
| Peiqing Liu | 206 | 37 | 14 | 26 | 15 | 360 |
All Works
Login with ORCID to disown or claim papers
Loading papers...